GLP-1 companion foods: Overview
- GLP-1 medication use is rising, creating demand for tailored nutritional products
- Smaller portions increase the importance of protein, fibre and micronutrient density
- Changing taste preferences favour less sweet, salty and fatty foods
- Potential microbiome changes create opportunities for targeted fibres and functional ingredients
Glucagon-like peptide-1 (GLP-1) receptor agonists (RAs) such as semaglutide (Ozempic, Wegovy, etc.) and tirzepatide (Mounjaro) have changed the obesity and weight loss landscape.
Around 12% of US adults have used GLP-1 medications for weight loss. And while take-up in Europe has been slower – only around 2% of adults – consumer interest is now growing fast and analysts are predicting a CAGR of between 5 and 12% over the coming years (Europe Glucagon-Like Peptide-1 Agonists Market Size & Share Analysis - Growth Trends and Forecast (2027 - 2032), 2026).
That raises the question of how the food industry can support GLP-1 medication users. While not yet fully understood, scientific evidence on how GLP-1 RAs affect food choices could point the industry in the right direction.
More nutrients in smaller portions
One of the ways GLP-1 RAs help people lose weight is by controlling appetite. People using these medications feel full quicker and so eat smaller portions and less food overall. This is great for weight loss but, if not managed properly, it can risk nutrient deficiencies and loss of muscle mass. Food manufacturers can help minimise this risk by offering products that provide essential nutrients such as protein, fibre and micronutrients in higher densities – so-called GLP-1 companion foods.
The challenge is how to increase the nutrient density enough to support GLP-1 RA users and still deliver a product that is nice to eat. Increasing protein and fibre levels needs to be done with care as, above certain levels, they can impact both the taste and texture of food. For example, many plant-based proteins bring off flavours, while excessive protein and fibres can lead to grittiness.
A question of taste and texture
This challenge is exacerbated by a second, less well-known effect of GLP-1 RAs. There is growing evidence to suggest that medications also change people’s food preferences, taste perception and eating patterns. Some studies suggest that people taking GLP-1 medications have less desire for sweet, salty and fatty foods. The effect seems to vary with the medication and method of delivery, so this is an area ripe for further scientific investigation. But it could already be a pointer towards the kind of flavour profiles manufacturers should be aiming for in companion foods.
What is more well established is a preference for smoother, creamier foods when taking GLP-1 medications. Delivering a smooth consistency in highly nutrient-dense foods is challenging, but not impossible. It can be achieved through the right combination of ingredients and processing technologies such as different approaches to heating or homogenisation.
Beyond food choices
It may not just be food preferences that change. Some studies have shown intriguing hints that taking GLP-1 RAs can lead to changes in the gut microbiome composition. As the medications suppress appetite, this may be partly related to people eating less – and especially less fibre. But there is also a suggestion of medication-specific changes.
More research is needed: first to confirm the effects and second to understand the functional impact on the microbiome. Interestingly, it has even been suggested that differences in baseline microbial signatures may partly explain why GLP-1 medications are more effective for some people than others.
If GLP-1 medication use does indeed lead to functional changes in the gut microbiome, this could open opportunities for new food products that help mitigate any negative effects. Possibilities include adding specific fibres to promote the growth of key microbial populations affected by the medications or even replacing the crucial metabolites that these populations would usually produce.
DIY GLP-1
While these possibilities are aimed at supporting people while they use GLP-1 RAs, this also raises another interesting possibility. GLP-1 RA medications mimic GLP-1, a naturally occurring hormone that is released in the intestine in response to certain nutrients. Endogenous GLP-1 production is induced by, for instance, peptides and amino acids from protein digestion and short-chain fatty acids produced by gut microbes metabolising fibre.
This raises the possibility of designing food products to naturally enhance GLP-1 production in the gut. For example, high-protein drinks could be used as a pre-meal strategy to improve postprandial responses and trigger satiety signals earlier.
Endogenous GLP-1 secretion doesn’t offer prolonged effects comparable to GLP-1 RA medications. But such food products could form a valuable part of consumers’ GLP-1 weight management journeys and address needs of people who can’t or don’t want to rely on medication.
The way ahead
Both GLP-1 companion foods and GLP-1 stimulating products mean increasing the levels of certain nutrients. That brings all the usual challenges of increasing nutrient density while delivering a product that tastes good and eats well. Many of the components to be added can affect flavour and mouthfeel.
Fortunately, the food industry has various tools to overcome this challenge through a combination of carefully selected ingredients and processing technologies. Moreover, manufacturing steps such as milling and thermal treatments alter matrix characteristics (such as particle size, denaturation and solubilisation) that impact the body’s ability to sense nutrients and, hence, GLP-1 production – providing a means to optimise products that aim to increase GLP-1 circulation.
The study of how GLP-1 medications affect food choices and the gut microbiome may still be in its early days. But the evidence is certainly strong enough to encourage the development of first-generation companion products that could reduce the risk of nutrient deficiencies during weight loss. Further research could lead to innovative weight-management food products that address individual consumer needs states before, during and after GLP-1 medication, ushering in a boom in more-tailored companion products.



